News & Press

Filter by year:

GeNeuro: financial information and business update for the second quarter 2019

Geneva, Switzerland, July 18, 2019, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported on its 2019 second quarter cash position and issued a business update.

HERV: A BBC4 radio interview of Prof. Patrick Küry

...

GeNeuro: Frontiers in Genetics review supports role of hidden DNA viruses in neurological disorders

  

PNAS publication supports temelimab’s rationale against neurodegeneration in MS

  

Multiple Sclerosis News Today

Protein Linked to Microglia Cell Activation and Nerve Fiber Damage in Study That Also Notes Potential Treatment

www.multiplesclerosisnewstoday.com

PNAS publication supports temelimab’s rationale against neurodegeneration in MS

Geneva, Switzerland, June 26, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), is delighted to announce that data supporting the mode of action of its lead product (temelimab) in treating MS was published in the Proceedings of the National Academy of Sciences (PNAS). Temelimab is a monoclonal antibody designed to neutralize a pathogenic, viral envelope protein, pHERV-W Env, which plays a causal role in the development of MS.

GeNeuro Shareholders Approve all Proposals at AGM

Geneva, Switzerland, 3 June, 2019 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced the approval by shareholders of all resolutions proposed at its Annual General Meeting (AGM) of 24 May, 2019.

GeNeuro’s Temelimab Phase IIa Data in Type 1 Diabetes at 12 Months Confirms RAINBOW Positive Results

Geneva, Switzerland, 7 May 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that a six-month extension of its Phase IIa study of temelimab (GNbAC1) in T1D confirmed all previouslyobserved positive observations in the trial, meeting its primary objective. GeNeuro believes these data open the door to further development in early-onset T1D pediatric patient population.

GeNeuro: Cash position at 31 March 2019 and Business Review

Geneva, Switzerland, April 24, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported on its 2019 first quarter cash position and issued a business update.

GeNeuro Reports 2018 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 1, 2019 –  GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS) and Type-1 Diabetes (T1D), today reported its full-year results for the year ended December 31, 2018 and provided a corporate update.


Results 1-10 of 14      Next Page      Last Page